SV 102
Alternative Names: SV-102; SYNC-T SV-102Latest Information Update: 12 Aug 2024
At a glance
- Originator Syncromune
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 01 Aug 2024 Syncromune plans a phase Ib LEGION-100 trial for Prostate cancer (Hormone-refractory, Metastatic-disease, Late-stage disease) (Intratumoural, Infusion) in September 2024 (NCT06533644)
- 01 Jul 2024 SV 102 receives Fast Track designation for Prostate cancer (Metastatic disease, Hormone refractory) in USA (Intratumoural)
- 31 May 2024 US FDA approves IND application for SV 102 in metastatic castrate-resistant prostate cancer